Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

recordati rare diseases, inc. - succimer (unii: dx1u2629qe) (succimer - unii:dx1u2629qe) - succimer 100 mg - chemet is indicated for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 mcg/dl. chemet is not indicated for prophylaxis of lead poisoning in a lead-containing environment; the use of chemet should always be accompanied by identification and removal of the source of the lead exposure. chemet should not be administered to patients with a history of allergy to the drug.

Europska Unija - engleski - EMA (European Medicines Agency)

recordati rare diseases - ibuprofen - ductus arteriosus, patent - cardiac therapy - treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

Europska Unija - engleski - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - pituitary and hypothalamic hormones and analogues - signifor is indicated for the treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

Europska Unija - engleski - EMA (European Medicines Agency)

recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitamins - vedrop is indicated in vitamin-e deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.

Europska Unija - engleski - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat phosphate - cushing syndrome - corticosteroids for systemic use - isturisa is indicated for the treatment of endogenous cushing’s syndrome in adults.

Irska - engleski - HPRA (Health Products Regulatory Authority)

recordati rare diseases - human hemin - concentrate for solution for infusion - 25 milligram(s)/millilitre - other hem products; hematin

Australija - engleski - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.